Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

R-011

Supelco

Ritalinic acid hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H17NO2 · HCl
CAS Number:
19395-40-5
Molecular Weight:
255.74
EC Number:
200-659-6
MDL number:
MFCD16294270
UNSPSC Code:
41116107
PubChem Substance ID:
329823972
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

Cl.OC(=O)C(C1CCCCN1)c2ccccc2

InChI

1S/C13H17NO2.ClH/c15-13(16)12(10-6-2-1-3-7-10)11-8-4-5-9-14-11;/h1-3,6-7,11-12,14H,4-5,8-9H2,(H,15,16);1H

InChI key

SCUMDQFFZZGUQY-UHFFFAOYSA-N

General description

Ritalin®ic acid is a primary blood metabolite of methylphenidate, a psychostimulant sold under trade names Concerta® and Ritalin®. This Certified Snap-N-Spike® Solution is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis. Methylphenidate is prescribed for treatment of attention-deficit hyperactivity disorder (ADHD), tachycardia, and narcolepsy.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Concerta is a registered trademark of ALZA Corporation
Ritalin is a registered trademark of Novartis Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Emilia Marchei et al.
Therapeutic drug monitoring, 32(4), 508-511 (2010-06-11)
The pharmacokinetics of methylphenidate (MPH), a prescription amphetamine derivative used in the treatment of attention-deficit hyperactivity disorder, has been amply described in conventional biological matrices. Recently, the excretion of MPH and its principal metabolite, ritalinic acid (RA) in oral fluid
Steve K Teo et al.
Journal of clinical pharmacology, 44(2), 173-178 (2004-01-30)
Attention deficit hyperactivity disorder (ADHD) in children is effectively treated by racemic oral methylphenidate (dl-MPH). The d-isomer (d-MPH) has been developed as an improved treatment for ADHD since only half the racemic dose is used. This study, performed in healthy
Maria del Mar Ramirez Fernandez et al.
Journal of analytical toxicology, 31(8), 497-504 (2007-11-09)
A validated method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and several metabolites is presented. The procedure comprises a sample clean-up step, using mixed-mode solid-phase extraction followed by liquid chromatography (LC)-tandem mass spectrometry analysis. Chromatographic separation
Emilia Marchei et al.
Clinical chemistry, 56(4), 585-592 (2010-02-20)
We studied the excretion profile of methylphenidate (MPH) and its metabolite ritalinic acid (RA) in oral fluid and plasma, the oral fluid-to-plasma (OF/P) drug ratio, and the variations of oral fluid pH after drug administration. We analyzed oral fluid and
Michaela Koehm et al.
Arzneimittel-Forschung, 60(5), 238-244 (2010-06-11)
In view of the widespread application of methylphenidate for attention-deficit/ hyperactivity disorder (ADHD) therapy its interaction with alcohol was investigated in an in-vitro assay and in a study involving 9 male volunteers. The study conditions were: methylphenidate (20 mg) only
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service